body increases the risk of infection, and can trigger immune responses, resulting in pain and swelling.The worm also can be excised surgically.Local cleaning of the lesion, and antibiotics for any bacterial superinfection.There is no curative antihelminthic treatment available. Metronidazole or tiabendazole have been used in adults as an adjunct to the extraction process, but one study found
) infections is based on drug treatment, improved sanitation and health education.Antihelmintic drugs (eg, mebendazole, albendazole and tiabendazole) are often used for both symptomatic infections and for large-scale prevention of morbidity in children living in endemic areas. This has resulted in improvements in child health and education after deworming.Concerns about the sustainability of periodic
involvement.CT/MRI scan of the brain may show meningeal/cerebral involvement.Tissue biopsy may be necessary.Toxocariasis treatment and managementThe mainstay of treatment includes anthelmintics (eg, albendazole, mebendazole or tiabendazole) and anti-inflammatory drugs. These drugs are used to achieve a clinical resolution or to reduce the damage caused by larval migration to various organs, particularly
for infections with severe symptoms).Mebendazole, albendazole or tiabendazole can kill adult worms in the intestine and are therefore effective if used within 1 week of eating contaminated meat to kill worms in the intestine and prevent systemic spread of larvae.There is no antihelminthic treatment that kills the larvae but albendazole may be be marginally effective. The mainstay of treatment once larval
. Diagnosis is made clinically in the presence of a linear serpiginous track moving forward in the skin, associated with itching and a history of exposure. Itching is typically very intense and can prevent patients from sleeping. Bacterial superinfection occurs as a result of scratching. Treatment is based on oral drugs (albendazole or ivermectin) or the topical application of tiabendazole. To control
Randomized trial of albendazole versus tiabendazole plus flubendazole during an outbreak of human trichinellosis. To determine the therapeutic usefulness of benzimidazoles in trichinellosis, 117 patients from a single outbreak were treated either with albendazole alone (N = 59) or with a regimen including tiabendazole followed by flubendazole (N = 58). The criteria of disease activity were evaluated at days 1, 7, 15, and 45. No difference was found between the two groups with regard to the evolution of myalgia, fever, fatigue, new clinical manifestations, or laboratory and serologic data. Both treatment regimens were well tolerated. In all, 30 patients of the albendazole group and 29 of the tiabendazole-flubendazole group were reevaluated 16 months later. Serology was negative in 70